一分钟看懂
这是一项关于尿路上皮癌的III 期研究，登记的药物或干预包括Sacituzumab tirumotecan；Vinflunine；Docetaxel；Paclitaxel；Rescue medications for sacituzumab tirumotecan；Rescue medications for chemotherapy，当前状态为招募中。登记地点显示中国北京、重庆、广州、珠海等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Sacituzumab tirumotecan；Vinflunine；Docetaxel；Paclitaxel；Rescue medications for sacituzumab tirumotecan；Rescue medications for chemotherapy · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University First Hospital ( Site 0184) · 北京
- The First Affiliated Hospital of Chonqing Medical University ( Site 0197) · 重庆
- Sun Yat-Sen University Cancer Center ( Site 0183) · 广州
- Sun Yat-Sen University Cancer Center ( Site 0188) · 广州
- Zhujiang Hospital of Southern Medical University ( Site 0205) · 广州
- The Fifth Affiliated Hospital of Sun Yat-Sen University ( Site 0900) · 珠海
- Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0198) · 武汉
- The Second Xiangya Hospital of Central South University ( Site 0916) · 长沙
- Jiangsu Cancer Hospital ( Site 0917) · 南京
- Jiangxi Cancer Hospital ( Site 0192) · 南昌
- Fudan University Shanghai Cancer Center ( Site 0181) · 上海
- Zhongshan Hospital Fudan University ( Site 0907) · 上海
- West China Hospital of Sichuan University ( Site 0185) · 成都
- The Second Hospital of Tianjin Medical University ( Site 0910) · 天津
- The First Hospital of Jiaxing ( Site 0901) · 嘉兴
- The First Affiliated Hospital of Ningbo University ( Site 0193) · 宁波
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0186) · 温州
- The First Affiliated Hospital of Wenzhou Medical University ( Site 0194) · 温州
公开的入选条件
- The main inclusion criteria include but are not limited to the following:
- * Has histologically documented locally advanced/metastatic urothelial cancer. Locally advanced disease must not be amenable to resection or radiation with curative intent per investigator assessment
- * Has measurable disease per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as assessed by the investigator
- * Has received treatment with anti-programmed cell death \[ligand\] 1 (anti-PD-\[L\]1) therapy, platinum-based chemotherapy, and enfortumab vedotin (EV)
- * Prior therapy with disitamab vedotin (DV) is allowed but will not meet the requirement for prior treatment with EV, except in China, where participants may have received DV instead of EV before study entry
- * Has received a maximum of 2 prior lines of therapy
- * Has experienced radiographic disease progression on or after the immediate prior line of therapy before study entry
- * Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07419295；登记信息更新于 2026-09-17。